Elevidys sales weaken; Neumora gets into obesity
Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.
Previous Post
STAT+: How a Colorado dietitian became Instagram’s top MAHA critic
Next Post
Physiotherapists could prescribe pregabalin again to take pressure off GPs
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago